Biotech | January 18, 2022
Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The company has 47 ANDA's pending approval with the U.S.FDA
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
The stability is led by healthy demand in the domestic and emerging markets
Ind-Ra expects revenue growth of over 12% in 2022.
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Subscribe To Our Newsletter & Stay Updated
